• First Patient Enrolled in Primary Sclerosing Cholangitis Trial americanpharmaceuticalreview
    August 13, 2019
    Immunic announced enrollment of the first patient in an investigator-sponsored proof-of-concept clinical trial of IMU-838 for the treatment of patients with primary sclerosing cholangitis (PSC). IMU-838 is an orally available ...
PharmaSources Customer Service